Canagliflozin

BNF:: 6.1.2.3
Status:: Grey
Decision Date:: July 2016

Comments

GREY:

Type 2 Diabetes without CKD

by exceptionality defined as intolerance to the preferred 1^st line choice or restricted by its licensing. (Decision date - July 2016).
NICE TA315: in combination therapy for treating type 2 diabetes. (Decision date - July 2014).
NICE TA390: as monotherapy for treating type 2 diabetes.

See local type 2 diabetes guidance.

GREY:

Type 2 diabetes with CKD

NICE NG28 and NG203 for adults with CKD and type 2 diabetes, in additions to an ACEI or ARB at an optimised dose. (Decision date - Sep 2021, updated Dec 2021, further update Dec 2022).